ARQT - Arcutis' roflumilast cream granted FDA approval for plaque psoriasis

• The U.S. FDA has approved Arcutis Biotherapeutics' ( NASDAQ: ARQT ) Zoryve (roflumilast) cream for plaque psoriasis in those 12 years old and up.
• The stock is up 6.5% in after-hours trading.
• The once-daily treatment is the first topical PDE4 inhibitor approved.
• Zoryve should be available beginning in mid-August.
• Arcutis ( ARQT ) plans to tap an additional $125M tranche as part of a non-dilutive financing agreement with SLR Capital Partners, adding that with other financial resources on hand, it will have more than $400 million to support the launch and commercialization efforts for ZORYVE, as well as advance the pipeline.
• Seeking Alpha's Quant Rating views Arcutis ( ARQT ) as hold with the only high grade being for momentum .

For further details see: